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Background: To date, more than 125 species of nontuberculous mycobacteria (NTM) have been identified. In this
study, we investigated the frequency and clinical implication of the rarely isolated NTM from respiratory specimens.
Methods: Patients with NTM isolated from their respiratory specimens between July 1, 2010 and June 31, 2012
were screened for inclusion. Rare NTM were defined as those NTM not falling within the group of eight NTM
species commonly identified at our institution: Mycobacterium avium, M. intracellulare, M. abscessus, M. massiliense,
M. fortuitum, M. kansasii, M. gordonae, and M. peregrinum. Clinical, radiographic and microbiological data from
patients with rare NTM were reviewed and analyzed.
Results: During the study period, 73 rare NTM were isolated from the respiratory specimens of 68 patients. Among
these, M. conceptionense was the most common (nine patients, 12.3%). The median age of the 68 patients with rare
NTM was 68 years, while 39 of the patients were male. Rare NTM were isolated only once in majority of patient
(64 patients, 94.1%). Among the four patients from whom rare NTM were isolated two or more times, only two
showed radiographic aggravation caused by rare NTM during the follow-up period.
Conclusions: Most of the rarely identified NTM species were isolated from respiratory specimens only once per
patient, without concomitant clinical aggravation. Clinicians could therefore observe such patients closely without
invasive work-ups or treatment, provided the patients do not have decreased host immunity towards mycobacteria.
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Nontuberculous mycobacteria (NTM) are defined as myco-
bacteria other than Mycobacterium tuberculosis complex
and M. leprae. Since the recognition of NTM as possible
pathogens in the 1950s [1,2], the observed occurrence of
NTM lung diseases has been increasing worldwide [3-5].
This may be attributed in part to improvements in micro-
bial diagnostic tools leading to increased isolation of NTM.
Additionally, the concomitant increase in susceptible hosts
such as patients with underlying lung disease or an im-
munocompromised state may also contribute to the
observed increase in NTM lung disease [5-9].
Presently, more than 125 classes of NTM species have
been identified [10]. Furthermore, newly identified spe-
cies of NTM are constantly reported owing to advances* Correspondence: yimjj@snu.ac.kr
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new species such as M. fragae and M. paragordonae
were identified as recently as 2013 [11,12].
Although the clinical characteristics of diseases caused
by commonly isolated NTM such as M. avium, M. intra-
cellulare or M. abscessus are well known, those caused by
newly recognized and rarely isolated NTM are not yet
fully understood. In the present study, we investigated the
frequency of rare NTM isolation and the clinical charac-
teristics of patients with rare NTM.Methods
Study population
Patients from whom NTM were isolated one or more
times from respiratory specimens such as sputum,
bronchoscopic wash fluid and bronchoalveolar lavage
(BAL) fluid between July 1, 2010 and June 31, 2012
at Seoul National University Hospital, were included
in the analysis. Hence, a total of 2556 NTM isolatedis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 NTM commonly isolated from respiratory
specimens during the study period
Species N (%)
Mycobacterium avium complex
Mycobacterium avium 250 (34.2)
Mycobacterium intracellulare 252 (34.5)
Mycobacterium abscessus complex
Mycobacterium abscessus 93 (12.7)
Mycobacterium massiliense 53 (7.3)
Mycobacterium fortuitum 28 (3.8)
Mycobacterium gordonae 19 (2.6)
Mycobacterium kansasii 18 (2.5)
Mycobacterium peregrinum 17 (2.4)
Total 730 (100.0)
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lyzed retrospectively. The Institutional Review Board
of Seoul National University Hospital approved the
study protocol and waived the requirement for obtaining
patient consent.
Identification of NTM species
Respiratory specimens were decontaminated with 4%
sodium hydroxide (NaOH), homogenized, and concen-
trated by centrifugation at 3000 × g for 20 min. The proc-
essed sediments were stained using the Ziehl-Neelsen
method [13]. Concentrated specimens were cultured in
MGIT tubes (Becton-Dickinson and Co.; Sparks, MD,
USA) as well as in 3% Ogawa medium and observed
weekly for 6 or 9 weeks after inoculation, respectively.
Once cultured, M. tuberculosis and NTM were differen-
tiated using the Gen-Probe® method (Gen-Probe; San
Diego, CA, USA) [14]. Following isolation of a suspected
mycobacterial species, confirmation of NTM was per-
formed by analyzing the sequences of three genes: 16S
rRNA, rpoB, and tuf. Polymerase chain reaction (PCR)
and subsequent sequence were performed and the
resulting sequences were compared with those in the
reference database using the basic local alignment search
tool (BLAST). Mycobacterial species were identified using
the 16S rRNA sequences and the algorithm described in
the Clinical and Laboratory Standards Institute guidelines
MM18-A [15].
Definition of rare NTM
For the purposes of this study, ‘rare NTM’ were defined
as NTM species other than M. avium, M. intracellulare,
M. abscessus, M. massiliense, M. fortuitum, M. kansasii,
M. gordonae and M. peregrinum, which are the eight
NTM species commonly identified at our institution.
Clinical and radiographic characteristics
Demographic, clinical and radiographic data of the
patients from whom rare NTM were isolated were
reviewed. Demographic data including age, gender, and
smoking habits; past medical history of tuberculosis
(TB), measles, pertussis, and sinusitis; comorbidities in-
cluding malignancy, diabetes mellitus, cerebrovascular
disease, rheumatic disease, inflammatory bowel disease,
gastroesophageal reflux disease, and underlying lung
disease; clinical data for self-reported symptoms; and
findings of the physical examinations, were all thor-
oughly reviewed. The characteristics and distribution of
lung lesions were analyzed based on chest computed tom-
ography (CT) by two pulmonologists (J.K. and J.J.Y.), who
were aware of the patients’ NTM results. Patients from
whom rare NTM were isolated more than once were
analyzed separately.Results
Common NTM isolated from respiratory specimens
during the study period
During the study period, 2554 NTM were isolated from
1373 patients. Of these, 803 NTM were identified at the
species level. Among these, 730 (90.9%) were commonly
isolated NTM species while the others (73 specimens,
9.1%) were rare NTM. M. avium (250 specimens, 34.2%)
and M. intracellulare (252 specimens, 34.5%) were the
most frequently identified rare NTM species, followed
by M. abscessus (93 specimens, 12.7%; see Table 1).
Rare NTM isolated during the study period
During the study period, 73 NTM isolated from 68 pa-
tients were identified as rare NTM. Of those isolated, 70
(95.9%) were from sputum and three (4.1%) were from
bronchoscopic specimens such as bronchial washsing
and bronchoalveolar lavage. Among the identified rare
NTM, M. conceptionense was the most common (nine
specimens, 12.3%), followed by M. chelonae, M. lentifla-
vum and M. mageritense (seven specimens each, 9.6%
respectively; Table 2). Rare NTM were isolated only
once from 64/68 patients, twice from three patients, and
three times from one patient. Among the patients from
whom rare NTM was isolated only once, commonly iso-
lated NTM was also isolated 2.4 times from 8.2 samples
of sputum on average.
Characteristics of the patient cohort from whom rare
NTM were isolated
The median age of the 68 patients from whom rare NTM
were isolated was 68 years (range, 30–84 years), while 39
(57.4%) were male. Of these patients, 24 (35.3%) had a
previous history of TB treatment. The most common
underlying diseases were solid organ malignancies includ-
ing lung cancer (seven patients, 10.3%), and diabetes
Table 2 Rare NTM species isolated from respiratory
specimens during the study period
Species N (%)
Mycobacterium conceptionense 9 (12.3)
Mycobacterium chelonae 7 (9.6)
Mycobacterium lentiflavum 7 (9.6)
Mycobacterium mageritense* 7 (9.6)
Mycobacterium chimaera† 6 (8.2)
Mycobacterium terrae 5 (6.8)
Mycobacterium kumamotonense 4 (5.5)
Mycobacterium porcinum 3 (4.1)
Mycobacterium goodie 2 (2.7)
Mycobacterium nebraskense 2 (2.7)
Mycobacterium phocaicum* 2 (2.7)
Mycobacterium septicum 2 (2.7)
Mycobacterium celatum 1 (1.4)
Mycobacterium holsaticum 1 (1.4)
Mycobacterium senuense 1 (1.4)
Mycobacterium arupense 1 (1.4)
Mycobacterium kubicae 1 (1.4)
Mycobacterium neoaurum 1 (1.4)
Mycobacterium xenopi 1 (1.4)
Failed species identification‡ 10 (13.7)
Total 73 (100.0)
*M. mageritense and M. phocaicum were isolated from a single patient.
†M. chimaera was isolated three times from a single patient.
‡Identification was attempted but failed at species level.
Table 3 Demographics and clinical characteristics of the
patient cohort from whom rare NTM were isolated
Demographics N (%)
Age (year), median (range) 68.0 (30.0–84.0)
Sex (Male) 39/68 (57.4)
Body Mass Index (kg/m2), median (range) 22.4 (15.9–29.0)
Habitual factors N (%)
Smoking 19/68 (33.8)
Ex-smoker 13/68 (22.4)
Current smoker 6/68 (10.3)
Past medical history N (%)






Lung cancer 1/68 (1.5)
Diabetes 6/68 (8.8)
Cerebrovascular disease 2/68 (2.9)
Rheumatoid arthritis 3/68 (4.4)
Inflammatory bowel disease 0/68 (−)




TB-destroyed lung 3/68 (4.4)
Interstitial lung disease 1/68 (1.5)
Bronchiectasis 23/68 (33.8)
HIV infection 1/68 (1.5)








Weight loss 6/68 (8.8)
Physical examination N (%)
Postnasal drip 10/68 (14.7)
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in two patients and HIV infection was confirmed in one
patient. Sputum production (39 patients, 57.4%) and
coughing (30 patients, 44.1%) were the most common self-
reported symptoms. Postnasal drip (10 patients, 14.7%)
and crackles (four patients, 5.8%) were the most common
findings during physical examination (Table 3).
Upper lobes of lung were commonly involved (right
upper lobe in 40 patients and left upper lobe in 33
patients). Bilateral lesions were found in 30 patients
(44.1%). In 21 (30.9%) patients, three or more lobes were
involved. Multiple nodules were the most commonly ob-
served radiographic finding (42 patients, 61.8%). Bron-
chiectasis (24 patients, 35.3%) and cavities (13 patients,
19.1%) were also commonly observed in radiographic ex-




Peripheral edema 0/68 (−)Clinical course of four patients from whom rare NTM
were isolated more than once
Four patients from whom rare NTM were isolated two
or more times had follow-ups for a median duration of
378 days (range, 294–477 days). Initial chest CT showed
Table 3 Demographics and clinical characteristics of the
patient cohort from whom rare NTM were isolated
(Continued)
Drug use
TNF-alpha inhibitor* 1/68 (1.5)
Steroid (5–10 mg daily)* 3/68 (4.4)
Other immunomodulatory drugs* 2/68 (2.9)
*All these drugs were used for the treatment of patients with
rheumatoid arthritis.
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(patients 1, 3 and 4), consolidations (patients 2 and 4), and
cavities (patient 4). In one patient (patient 2 in Table 5)
from whom rare NTM as well as M. abscessus was iso-
lated, the respiratory symptoms were aggravated and
radiographic lesions progressed on follow-up chest CT.
The clinician who managed this patient judged that this
progression was caused by M. abscessus rather than M.
goodie. Subsequently, a clarithromycin-based regimen was
initiated for this patient. Negative conversion of sputum
culture was not however achieved with treatment despite
a slight symptomatic improvement. In the other two pa-
tients (patients 1 and 3 in Table 5), neither aggravation of
symptoms nor progression of radiographic lesions on




Right upper lobe 40/68 (58.8)
Right middle lobe 21/68 (30.9)
Right lower lobe 22/68 (32.4)
Left upper lobe 33/68 (48.5)
Left lower lobe 21/68 (30.9)
Lesion distribution
Bilateral 30/68 (44.1)
Multilobar (≥3 lobes with abnormalities) 21/68 (30.9)
Lesion characteristics






Upper lobe cavitary pattern 12/68 (17.6)
Nodular bronchiectatic pattern 17/68 (25.0)
Unclassifiable 39/68 (57.4)without concomitant anti-NTM treatment. The other pa-
tient from whom M. chimaera was isolated at three sep-
arate time points (patient 4 in Table 5) developed new
centrilobular nodules. However, this patient’s other
symptoms did not change and no treatment was applied
(Table 5).
Discussion
New NTM are constantly reported, while the lung dis-
eases arising from these new organisms are reported at a
similarly rapid rate [16-19]. Consequently, clinicians in-
evitably encounter patients who present with unfamiliar
and rarely identified NTM.
In the present study, various species of rarely identi-
fied NTM were isolated from respiratory specimens. M.
conceptionense was the most frequently isolated rare
NTM. This species was reported to cause infections of
the skin and subcutaneous fat following surgical proce-
dures in immunocompetent patients [20-22]. Moreover,
another study demonstrated that this NTM may be a
lung pathogen [18]. However, in our study, for the
patient from whom M. conceptionense was isolated at
two separate time points, neither aggravation of the
symptoms nor progression of radiographic lesions was
identified.
Other rare NTM species isolated from patients in the
present study (M. lentiflavum, M. mageritense, M. chimaera
and M. xenopi) may also cause lung diseases [16,18,19,23].
However, yet other rare NTM isolated from these patients,
such as M. kumamotonense and M. celatum, have generally
been considered to be misidentifications or a result of cul-
ture contamination, and are thus deemed to be clinically
non-pathogenic organisms [24,25].
NTM classified as rarely isolated NTM in this study
may prove common in other geographic regions. For ex-
ample, M. xenopi is commonly identified in southern
Ontario, South East England and Europe [26,27], but
rarely in Australia, South America, USA and Asia [28,29].
However, in this study performed in South Korea, M.
xenopi was isolated only once.
Despite their pathogenic potential, among the patients
from whom rare NTM were identified, rare NTM were
isolated only once in the majority of patients (64/68).
Once-off isolation of the majority of the rare NTM
suggests limited clinical significance of these NTM.
Additionally, the observation that only one of the three
patients from whom rare NTM were isolated two or more
times without co-infection with common NTM showed
evidence of radiographic aggravation, further substantiates
the minimal clinical significance of rare NTM.
The limited clinical importance of the frequent one-
time isolation of rare NTM presented in this study
underscores the importance of the current ATS/IDSA
diagnostic guidelines, which require repeated isolation of
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cians confronted with rare NTM could observe the pa-
tients for a while watching whether the same species of
NTM would be isolated again or not.
To fully appreciate these results, a limitation of this
study should be noted: species level identification was
not performed on all NTM isolated from respiratory
specimens. A prospective study including species identi-
fication of all NTM isolated during the certain period
would likely confirm the findings of the current study.
Conclusions
Rarely identified NTM isolated from respiratory speci-
mens have limited clinical importance in most cases. Cli-
nicians who treat patients with rarely identified NTM
could therefore observe them closely without any inten-
sive work-ups or treatment being required, provided that
these patients do not present with decreased host im-
munity towards mycobacteria.
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